Is a regimen of fluoxetine 60 mg daily plus aripiprazole 5 mg daily appropriate for an adult with severe obsessive‑compulsive disorder (OCD) and major depressive disorder (MDD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fluoxetine 60mg Plus Aripiprazole 5mg for Severe OCD and MDD

Yes, this regimen is appropriate and evidence-based for severe OCD with comorbid MDD, though the aripiprazole dose may need titration upward if response is inadequate. This combination addresses both conditions effectively, with fluoxetine at 60mg being within the FDA-approved range for OCD and aripiprazole serving as an evidence-based augmentation strategy 1, 2.

Rationale for This Regimen

Fluoxetine 60mg for OCD and MDD

Fluoxetine 60mg is an appropriate dose for severe OCD:

  • FDA-approved dosing for OCD ranges from 20-80mg daily, with 60mg falling well within this therapeutic window 2
  • The FDA label specifically notes that "a dose range of 20 to 60 mg/day is recommended" for OCD, with doses up to 80mg/day well-tolerated in open studies 2
  • For MDD, the maximum FDA-approved dose is 80mg/day, so 60mg is appropriate for comorbid depression 2
  • Higher SSRI doses are specifically recommended for OCD compared to depression or other anxiety disorders 1

Critical timing consideration: The full therapeutic effect for OCD may be delayed until 5 weeks of treatment or longer 2. Guidelines recommend 8-12 weeks at an adequate dose before determining treatment resistance 1.

Aripiprazole Augmentation Strategy

Aripiprazole augmentation is evidence-based for SSRI-resistant OCD, with meta-analytic support for both risperidone and aripiprazole 1. However, there are important nuances:

  • Only one-third of patients with SSRI-resistant OCD show clinically meaningful response to antipsychotic augmentation 1
  • The effect size for antipsychotic augmentation is smaller than SSRI monotherapy 1
  • Aripiprazole is also beneficial for comorbid MDD, making it particularly suitable for this dual diagnosis 3

Dose Considerations for Aripiprazole

The 5mg dose may be suboptimal. While this is a reasonable starting dose to assess tolerability:

  • Studies of aripiprazole in OCD have used doses ranging from 10-30mg/day 4
  • A 2021 comparative study showed significant improvement with aripiprazole augmentation, though specific doses weren't detailed 5
  • Consider titrating upward to 10-15mg if response at 5mg is inadequate after 4-6 weeks

Important Caveats and Monitoring

When This Regimen is Appropriate

This combination is most appropriate when:

  1. The patient has already failed adequate SSRI monotherapy (at least 8-12 weeks at therapeutic doses) 1
  2. Severe symptoms warrant aggressive treatment from the outset
  3. Comorbid MDD is present, as aripiprazole has benefits for both conditions 3

Alternative Strategies to Consider First

Before adding aripiprazole, ensure adequate fluoxetine monotherapy:

  • The most important factor in treatment response is time spent on fluoxetine monotherapy (6 months was optimal in one key trial) 1
  • Consider maximizing fluoxetine to 80mg/day before augmentation 2
  • CBT with exposure and response prevention (ERP) augmentation has larger effect sizes than antipsychotic augmentation 1

If augmentation is needed, clomipramine may be superior: In the only head-to-head RCT comparing augmentation strategies, fluoxetine plus clomipramine was significantly superior to fluoxetine plus quetiapine (another antipsychotic) 1, 6. However, this combination carries serious risks including seizures, cardiac arrhythmias, and serotonin syndrome due to drug-drug interactions 1.

Mandatory Safety Monitoring

Ongoing monitoring of the risk-benefit ratio is essential with antipsychotic augmentation 1:

  • Weight gain and metabolic dysregulation are the primary concerns
  • Monitor weight, fasting glucose, lipid panel at baseline, 3 months, and then annually
  • Assess for extrapyramidal symptoms (though aripiprazole has lower risk than other antipsychotics)
  • Monitor for akathisia, which can occur even at low doses 4

Treatment Duration

  • Minimum 12-24 months of pharmacotherapy after achieving remission is recommended for OCD 1
  • Many patients require longer treatment due to high relapse risk after discontinuation 1
  • For MDD, several months or longer of sustained therapy is needed 2

Clinical Algorithm

  1. If this is initial treatment: Start fluoxetine 20mg, titrate to 60mg over 4-6 weeks, wait full 12 weeks before adding augmentation
  2. If already on fluoxetine 60mg for 12+ weeks with inadequate response: Adding aripiprazole 5mg is reasonable, but plan to titrate to 10-15mg if needed
  3. If CBT/ERP is available: Prioritize this over antipsychotic augmentation
  4. If response remains inadequate: Consider switching to clomipramine plus fluoxetine (with careful monitoring) or trying alternative augmentation strategies like N-acetylcysteine or memantine 1

The proposed regimen is evidence-based and appropriate for severe OCD with MDD, particularly if prior adequate SSRI trials have failed, though optimizing fluoxetine monotherapy duration and considering CBT augmentation should be prioritized when feasible 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.